Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Mainz – page 31

604 clinical trials in Mainz, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Mainz at a glance
604
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

604 trials in Mainz

Open in trial search

Hereditary angioedema

Not recruiting

Safety Study of Switching from Current Treatment to Garadacimab in Patients Age 12 and Older with Hereditary Angioedema

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Garadacimab
  • Sponsor:CSL Behring LLC

Colorectal cancer

Not recruiting

A study of futibatinib combined with tislelizumab, fluorouracil, calcium folinate, and oxaliplatin as first-line treatment for patients with colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Hidradenitis

Not recruiting

Study of Bimekizumab for Children and Adolescents with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Influenza

Not recruiting

Study on the Safety and Immune Response of aQIVc HD Vaccine Compared to a Drug Combination for Adults 50 Years and Older at Risk of Flu Complications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/(H3N2)-LIKE VIRUS ANTIGEN
  • Sponsor:Seqirus UK Limited

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Coronavirus infection

Not recruiting

Study on COVID-19 Prevention Using Sipavibart and Cilgavimab for Patients with Weakened Immune Systems

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Cilgavimab
  • Sponsor:AstraZeneca AB

Herpes zoster

Not recruiting

Study on Long-Term Effects and Safety of Herpes Zoster Vaccine with Recombinant Varicella Zoster Virus Glycoprotein E in Older Adults

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:GlaxoSmithKline Biologicals

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Tolerability of VRDN-003 for Patients with Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003
  • Sponsor:Viridian Therapeutics Inc.

Chronic graft versus host disease

Not recruiting

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Endocrine ophthalmopathy

Not recruiting

Study on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003
  • Sponsor:Viridian Therapeutics Inc.

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Metastatic gastric cancer

Not recruiting

Study of M9140 for Patients with Advanced Stomach Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Mainz

What the registry says about research in the country

01 Infectious Disease Prevention

Groundbreaking trials focusing on viral infections including studies of vaccines against Respiratory Syncytial Virus, Herpes Zoster, and Cytomegalovirus. Research aims to evaluate vaccine efficacy and immune response in different age groups.

  • RSV and hMPV Prevention
  • Herpes Zoster Protection
  • CMV Vaccine Development

Special attention is given to protecting vulnerable populations, including older adults and those at increased risk.

02 Oncology Research

Innovative clinical trials targeting various forms of cancer, including studies on breast cancer, pancreatic cancer, and multiple myeloma. Research focuses on novel therapeutic approaches and combination treatments.

  • Advanced Breast Cancer Therapy
  • Gastric Cancer Treatment
  • Lymphoma Management

Emphasis on personalized medicine approaches and targeted therapies for better patient outcomes.

03 Chronic Disease Management

Comprehensive studies addressing respiratory conditions, autoimmune disorders, and metabolic diseases. Research includes treatments for asthma, multiple sclerosis, and obesity.

  • Pulmonary Hypertension
  • Chronic Kidney Disease
  • Autoimmune Conditions

Focus on developing long-term treatment solutions and improving quality of life for patients.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.